ClinicalTrials.gg
Not yet recruitingNCT04772651MeDiVaUpdated Mar 14, 2023

Mediterranean Diet and the Microbiota Gut Brain Axis in Major Depression

An interventional study of Mediterranean Diet and Normal hospital diet in Depression, sponsored by Medical University of Graz. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-03-14.

Sponsored by Medical University of Graz · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to assess the efficacy of a Mediterranean diet on the function of the vagal nerve in patients with depression.

Read the detailed description

After being informed about the study and potential risks, all patients giving written informed consent will be screened for eligibility. Subjects meeting the inclusion criteria will be randomized in a group recieiving a Mediterranean diet (3 mediterranean meals a day) and dietary coaching (1 session per week for 4 weeks) or a group with conventional hospital food and psychoeducation on depression (1 session per week for 4 weeks).

02

Conditions studied

  • Depression

Browse trials for

Keywords

  • nutrition
  • mediterranean diet
  • vagal function
  • heart rate variability
03

In context

Depression

8,240 studies on the registry are indexed under Depression; 1,641 are open to participants now.

This study's planned enrollment of 108 is above the median of 84 across 6,869 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

Medical University of Graz is the lead sponsor of 470 studies on the registry; 98 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • legally competent persons aged 18-80 years
  • diagnosis of depression according to ICD-10 or DSM.

Exclusion criteria

Exclusion Criteria:

  • other neurologic or psychiatric disorders (epilepsy, brain tumor, head injury, head surgery, trauma)
  • drug or alcohol dependency
  • acute suicidality
  • heart disorders, disorders of the circulatory system
  • pregnancy and period of breastfeeding
  • severe mental disability, dementia (MMST\<20)
  • autoimmune disorder, severe immunosuppression (Lupus, HIV, multiple sclerosis)
  • therapy with antibiotics in the last month
  • chronic laxative abuse
  • acute infectious diarrhea
  • GI surgeries (except appendectomy)
  • regular intake of probiotics, antibiotics and food supplements (1 month before and during the study)
  • food allergies or other food intolerances which are incompatible with a mediterranean diet
  • vegetarians, vegans
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    Mediterranean Diet and dietary coaching

    Patients receive 3 Mediterranean meals a day for 4 weeks and dietary coaching sessions (á 50 minutes once a week for 4 weeks)

    Other: Mediterranean Diet · Other: dietary coaching

  • Placebo comparator
    Diet as usual and psychoeducation for depression

    Patients receive normal hospital diet with 3 meals a day for 4 weeks and psychoeducation sessions (á 50 minutes once a week for 4 weeks)

    Other: Normal hospital diet · Other: Psychoeducation on depression

Interventions

  • OtherMediterranean Diet

    Diet meeting the requirements for mediterranean style (rich in vegetables, fruit, olive oil, fish) (Davis et al., 2015)

  • OtherNormal hospital diet

    Normal hospital diet

  • Otherdietary coaching

    dietary coaching

  • OtherPsychoeducation on depression

    Psychoeducation on depression (50minutes once a week for 4 weeks)

06

What researchers measure

Primary outcomes

  1. Change in Vagal function

    Vagal function measured by 24-hr ECG (logRSA, SDNN)

    Time frame: at study entry, after 7 days, after 4 weeks and after 3 months

Secondary outcomes

  1. Change of C-reactive protein (CRP)

    CRP will be measured from serum samples at the Institute of laboratory diagnostics (Cobas analyzer)

    Time frame: at study entry, after 7 days, after 4 weeks and after 3 months

  2. Change in Interleukine-6

    Interleukine-6 will be measured from serum samples at the Institute of laboratory diagnostics

    Time frame: at study entry, after 7 days, after 4 weeks and after 3 months

  3. Change in Oxytocin

    measured from serum samples with ELISA

    Time frame: at study entry, after 7 days, after 4 weeks and after 3 months

  4. Change of Gut microbiome

    16S sequencing of a stool sample, gut microbiome data will be analyzed with QIIME2 with regard to diversity metrices (alpha-diversity, beta-diversity) and differential bacterial abundance.

    Time frame: at study entry, after 7 days, after 4 weeks and after 3 months

  5. Change of Body mass Index

    Weight will be measured with a calibrated scale, height will be measured with a non-expandable measuring tape. BMI will be calculated according to the formula \[kg/m2\].

    Time frame: at study entry, after 7 days, after 4 weeks and after 3 months

  6. Change in Hamilton Scale for Depression (HAMD)

    Scale to rate severity of depressive symptoms; Scoring is based on the 17-item scale and scores of 0-7 are considered as being normal, 8-16 suggest mild depression, 17-23 moderate depression and scores over 24 are indicative of severe depression

    Time frame: at study entry, after 7 days, after 4 weeks and after 3 months

  7. Change in Beck Depression Inventory (BDI)

    Self-rated scale to rate severity of depressive symptoms; Total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depression.

    Time frame: at study entry, after 7 days, after 4 weeks and after 3 months

  8. Change in Pittsburgh Sleep Quality Inventory (PSQI)

    Questionnaire to assess sleep quality; global PSQI score is calculated by totaling the seven component scores, providing an overall score ranging from 0 to 21, where lower scores denote a healthier sleep quality.

    Time frame: at study entry, after 7 days, after 4 weeks and after 3 months

  9. Change in Adult Attachment Scale

    Questionnaire to assess attachment style in adults; The scale consists of 18 items scored on a 5 point likert-type scale. It measures adult attachment styles named "Secure", "Anxious" and "Avoidant", defined as: * Secure = high scores on Close and Depend subscales, low score on Anxiety subscale * Anxious = high score on Anxiety subscale, moderate scores on Close and Depend subscales * Avoidant = low scores on Close, Depend, and Anxiety subscales

    Time frame: at study entry, after 7 days, after 4 weeks and after 3 months

  10. Change in Wiener Ernährungsprotokoll

    24-hr food recall

    Time frame: at study entry, after 7 days, after 4 weeks and after 3 months

  11. Change in Mediterranean Diet Score

    Questionnaire rating the diet according to Mediterranean dietary style; three categories of adherence to the Mediterranean diet can be calculated (≤5, 6-9 and ≥10 points of the 14-item questionnaire)

    Time frame: at study entry, after 7 days, after 4 weeks and after 3 months

  12. Change in International Physical Acitivity Questionnaire

    Questionnaire to rate physical activity; Physical activity is given in MET-minutes (METs are multiples of the resting metabolic rate)

    Time frame: at study entry, after 7 days, after 4 weeks and after 3 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2025; primary completion for Sep 2028, 34 months later.

Of 3,016 non-industry interventional studies with no phase under Depression, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 34 months is above that.

Counting every sponsor, half of 3,112 studies reached it within 22 months; a quarter within 10 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2021
First posted
Feb 26, 2021
StartEst.
Nov 1, 2025
Primary completionEst.
Sep 1, 2028
CompletionEst.
Sep 30, 2029
Last update
Mar 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04772651
Responsible party
Sponsor
First posted
Feb 26, 2021
Start date
Nov 1, 2025 (estimated)
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 30, 2029 (estimated)
Last update
Mar 14, 2023

Study contacts

Sabrina Mörkl, DDr.
Contact
sabrina.moerkl@medunigraz.at
004331638581743
Eva Reininghaus, Prof.
Contact
eva.reininghaus@medunigraz.at

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion